CD274 and gastric cancer: For PD-1/PD-L1 inhibitors, trials such as KEYNOTE-016 have shown that pembrolizumab significantly improved PFS by approximately eight months compared to chemotherapy in MSI-H/dMMR mCRC, GC, and gastroesophageal junction cancer [347–350].